Overview
Transgenic manipulation is the name of the game at GTC Biotherapeutics. The firm makes its products by inserting human DNA into animals who then produce the protein in their milk; the proteins are purified from the milk and used for human treatments. This process of creating what are known as recombinant proteins makes it easier and cheaper to produce large quantities of certain therapeutic proteins. The company's first commercial product, ATryn,
...
Read More received European regulatory approval in 2006 and FDA approval in 2009; the product is a recombinant human antithrombin designed to help prevent blood clots. GTC is a wholly owned subsidiary of French firm LFB Biotechnologies.
Read Less
Read More received European regulatory approval in 2006 and FDA approval in 2009; the product is a recombinant human antithrombin designed to help prevent blood clots. GTC is a wholly owned subsidiary of French firm LFB Biotechnologies.
Read Less
William Heiden
See more contacts
Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
,
Pharmaceutical and Medicine Manufacturing
,
Real Estate and Rental and Leasing
,
Patent buying, licensing, leasing
,
Pharmaceutical preparations
?
?
?
Modelled
?
Actual
#
Modelled
?
?
Contacts
Get in Touch with 7 Principals* and 2 Contacts
-
William HeidenPresident and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.